| Hazard Information | Back Directory | [Uses]
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4+ and CD8+ cells in both human and mice. Efineptakin alfa can be used for glioblastoma research[1]. | [in vivo]
Efineptakin alfa (10 mg/kg, IM, single) combined with SLC-3010 (1.8 mg/kg, IV, single) inhibits tumor growth in MC38-bearing mice[1].
Efineptakin alfa (10 mg/kg) mitigates RT-related lymphopenia, increases cytotoxic CD8 T lymphocytes systemically and in the tumor, and improves survival in orthotopic glioma-bearing mice[2]. | Animal Model: | C57BL/6 mice bearing intracranial tumors (GL261 or CT2A)[1] | | Dosage: | 10 mg/kg | | Administration: | On the final day of RT (radiotherapy, 1.8 Gy/day × 5 days) completion | | Result: | Increased T lymphocytes in the lymph nodes, thymus, and spleen, enhanced IFNγ production, and decreased Tregs in the tumor which was associated with a significant increase in survival. Enhanced central memory and effector memory CD8 T cells in lymphoid organs and tumor. Decreased progenitor cells in the bone marrow. |
| [IC 50]
IL7R | [References]
[1] Campian JL, et al. Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models. Clin Cancer Res. 2022 Mar 15;28(6):1229-1239. DOI:10.1158/1078-0432.CCR-21-0947
[2] Seungtae Baek, et al. rhIL-7-hyFc (efineptakin alfa; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex. 2022 AACR Abstract #4199. |
|
|